Which has stronger valuation and earnings, BSX or STE?

Boston Scientific has higher revenue and earnings than STERIS. Boston Scientific is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Boston Scientific $20.07B 3.31 $2.90B $2.39 18.68 STERIS $5.94B 3.56 $782.30M $7.93 27.34

Does the media refer more to BSX or STE?

In the previous week, Boston Scientific had 17 more articles in the media than STERIS. MarketBeat recorded 22 mentions for Boston Scientific and 5 mentions for STERIS. STERIS's average media sentiment score of 1.48 beat Boston Scientific's score of 0.87 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Boston Scientific 13 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EW or STE?

In the previous week, Edwards Lifesciences had 11 more articles in the media than STERIS. MarketBeat recorded 16 mentions for Edwards Lifesciences and 5 mentions for STERIS. STERIS's average media sentiment score of 1.48 beat Edwards Lifesciences' score of 0.98 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edwards Lifesciences 9 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer STE or IDXX?

In the previous week, IDEXX Laboratories had 5 more articles in the media than STERIS. MarketBeat recorded 10 mentions for IDEXX Laboratories and 5 mentions for STERIS. STERIS's average media sentiment score of 1.48 beat IDEXX Laboratories' score of 0.99 indicating that STERIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEXX Laboratories 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor STE or BDX?

In the previous week, Becton, Dickinson and Company had 6 more articles in the media than STERIS. MarketBeat recorded 11 mentions for Becton, Dickinson and Company and 5 mentions for STERIS. STERIS's average media sentiment score of 1.48 beat Becton, Dickinson and Company's score of 1.22 indicating that STERIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Becton, Dickinson and Company 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, STE or RMD?

ResMed has lower revenue, but higher earnings than STERIS. ResMed is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio STERIS $5.94B 3.56 $782.30M $7.93 27.34 ResMed $5.15B 5.59 $1.40B $10.37 19.13

Is STE or RMD more profitable?

ResMed has a net margin of 27.44% compared to STERIS's net margin of 13.18%. ResMed's return on equity of 25.35% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets STERIS 13.18% 14.15% 9.52% ResMed 27.44% 25.35% 18.69%

Does the media refer more to STE or RMD?

In the previous week, ResMed had 22 more articles in the media than STERIS. MarketBeat recorded 27 mentions for ResMed and 5 mentions for STERIS. STERIS's average media sentiment score of 1.48 beat ResMed's score of 0.76 indicating that STERIS is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STERIS 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 12 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

STERIS (STE) Competitors

$216.84 +0.84 (+0.39%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$217.00 +0.16 (+0.07%)

As of 07/13/2026 06:18 PM Eastern

Compare

STE vs. BSX, EW, IDXX, BDX, and RMD

Should you buy STERIS stock or one of its competitors? MarketBeat compares STERIS with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with STERIS include Boston Scientific (BSX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), Becton, Dickinson and Company (BDX), and ResMed (RMD). These companies are all part of the "health care equipment" industry.

How does STERIS compare to Boston Scientific?

Boston Scientific (NYSE:BSX) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 0.3% of Boston Scientific shares are owned by insiders. Comparatively, 1.1% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Boston Scientific currently has a consensus target price of $80.72, indicating a potential upside of 80.80%. STERIS has a consensus target price of $278.00, indicating a potential upside of 28.21%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Boston Scientific is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Boston Scientific	2 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.77
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Boston Scientific has higher revenue and earnings than STERIS. Boston Scientific is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Boston Scientific	$20.07B	3.31	$2.90B	$2.39	18.68
STERIS	$5.94B	3.56	$782.30M	$7.93	27.34

Boston Scientific has a net margin of 17.29% compared to STERIS's net margin of 13.18%. Boston Scientific's return on equity of 19.17% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Boston Scientific	17.29%	19.17%	10.77%
STERIS	13.18%	14.15%	9.52%

In the previous week, Boston Scientific had 17 more articles in the media than STERIS. MarketBeat recorded 22 mentions for Boston Scientific and 5 mentions for STERIS. STERIS's average media sentiment score of 1.48 beat Boston Scientific's score of 0.87 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Boston Scientific	13 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Boston Scientific has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, STERIS has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

Summary

Boston Scientific beats STERIS on 10 of the 17 factors compared between the two stocks.

How does STERIS compare to Edwards Lifesciences?

Edwards Lifesciences (NYSE:EW) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

79.5% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 0.3% of Edwards Lifesciences shares are owned by insiders. Comparatively, 1.1% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Edwards Lifesciences currently has a consensus target price of $97.52, indicating a potential upside of 6.25%. STERIS has a consensus target price of $278.00, indicating a potential upside of 28.21%. Given STERIS's higher possible upside, analysts plainly believe STERIS is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0 Sell rating(s)	8 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.77
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Edwards Lifesciences has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.07B	8.71	$1.07B	$1.88	48.82
STERIS	$5.94B	3.56	$782.30M	$7.93	27.34

Edwards Lifesciences has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, STERIS has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

Edwards Lifesciences has a net margin of 17.39% compared to STERIS's net margin of 13.18%. Edwards Lifesciences' return on equity of 15.19% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	17.39%	15.19%	11.71%
STERIS	13.18%	14.15%	9.52%

In the previous week, Edwards Lifesciences had 11 more articles in the media than STERIS. MarketBeat recorded 16 mentions for Edwards Lifesciences and 5 mentions for STERIS. STERIS's average media sentiment score of 1.48 beat Edwards Lifesciences' score of 0.98 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edwards Lifesciences	9 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Edwards Lifesciences beats STERIS on 11 of the 17 factors compared between the two stocks.

How does STERIS compare to IDEXX Laboratories?

STERIS (NYSE:STE) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

STERIS presently has a consensus price target of $278.00, indicating a potential upside of 28.21%. IDEXX Laboratories has a consensus price target of $751.00, indicating a potential upside of 33.11%. Given IDEXX Laboratories' higher possible upside, analysts plainly believe IDEXX Laboratories is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64

IDEXX Laboratories has lower revenue, but higher earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.56	$782.30M	$7.93	27.34
IDEXX Laboratories	$4.30B	10.34	$1.06B	$13.58	41.55

STERIS has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, IDEXX Laboratories has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

94.7% of STERIS shares are owned by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are owned by institutional investors. 1.1% of STERIS shares are owned by insiders. Comparatively, 0.8% of IDEXX Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

IDEXX Laboratories has a net margin of 24.63% compared to STERIS's net margin of 13.18%. IDEXX Laboratories' return on equity of 70.87% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
IDEXX Laboratories	24.63%	70.87%	32.56%

In the previous week, IDEXX Laboratories had 5 more articles in the media than STERIS. MarketBeat recorded 10 mentions for IDEXX Laboratories and 5 mentions for STERIS. STERIS's average media sentiment score of 1.48 beat IDEXX Laboratories' score of 0.99 indicating that STERIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEXX Laboratories	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IDEXX Laboratories beats STERIS on 11 of the 16 factors compared between the two stocks.

How does STERIS compare to Becton, Dickinson and Company?

STERIS (NYSE:STE) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

In the previous week, Becton, Dickinson and Company had 6 more articles in the media than STERIS. MarketBeat recorded 11 mentions for Becton, Dickinson and Company and 5 mentions for STERIS. STERIS's average media sentiment score of 1.48 beat Becton, Dickinson and Company's score of 1.22 indicating that STERIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Becton, Dickinson and Company	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

STERIS has a net margin of 13.18% compared to Becton, Dickinson and Company's net margin of 5.33%. Becton, Dickinson and Company's return on equity of 15.37% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
Becton, Dickinson and Company	5.33%	15.37%	7.11%

STERIS currently has a consensus target price of $278.00, indicating a potential upside of 28.21%. Becton, Dickinson and Company has a consensus target price of $180.29, indicating a potential upside of 17.16%. Given STERIS's stronger consensus rating and higher possible upside, equities research analysts clearly believe STERIS is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38

Becton, Dickinson and Company has higher revenue and earnings than STERIS. STERIS is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.56	$782.30M	$7.93	27.34
Becton, Dickinson and Company	$21.84B	1.94	$1.68B	$3.95	38.96

STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.2%. Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 2.7%. STERIS pays out 31.8% of its earnings in the form of a dividend. Becton, Dickinson and Company pays out 106.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. STERIS has increased its dividend for 20 consecutive years and Becton, Dickinson and Company has increased its dividend for 53 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

STERIS has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Becton, Dickinson and Company has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

94.7% of STERIS shares are held by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 1.1% of STERIS shares are held by company insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

STERIS beats Becton, Dickinson and Company on 11 of the 19 factors compared between the two stocks.

How does STERIS compare to ResMed?

STERIS (NYSE:STE) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

In the previous week, ResMed had 22 more articles in the media than STERIS. MarketBeat recorded 27 mentions for ResMed and 5 mentions for STERIS. STERIS's average media sentiment score of 1.48 beat ResMed's score of 0.76 indicating that STERIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	12 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

STERIS has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, ResMed has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

ResMed has a net margin of 27.44% compared to STERIS's net margin of 13.18%. ResMed's return on equity of 25.35% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
ResMed	27.44%	25.35%	18.69%

STERIS presently has a consensus target price of $278.00, indicating a potential upside of 28.21%. ResMed has a consensus target price of $260.17, indicating a potential upside of 31.15%. Given ResMed's higher probable upside, analysts clearly believe ResMed is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
ResMed	0 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.59

ResMed has lower revenue, but higher earnings than STERIS. ResMed is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.56	$782.30M	$7.93	27.34
ResMed	$5.15B	5.59	$1.40B	$10.37	19.13

94.7% of STERIS shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 1.1% of STERIS shares are held by company insiders. Comparatively, 0.7% of ResMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

STERIS pays an annual dividend of $2.52 per share and has a dividend yield of 1.2%. ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.2%. STERIS pays out 31.8% of its earnings in the form of a dividend. ResMed pays out 23.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has increased its dividend for 20 consecutive years and ResMed has increased its dividend for 13 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

ResMed beats STERIS on 12 of the 20 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STE vs. The Competition

Export

Metric	STERIS	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$21.05B	$7.63B	$7.05B	$23.46B
Dividend Yield	1.17%	1.32%	2.68%	4.02%
P/E Ratio	27.34	50.28	27.11	31.08
Price / Sales	3.56	76.45	587.92	19.77
Price / Cash	14.22	26.85	29.22	18.64
Price / Book	2.95	7.32	10.75	4.77
Net Income	$782.30M	$162.30M	$3.58B	$1.06B
7 Day Performance	0.64%	-0.99%	-2.06%	-0.23%
1 Month Performance	4.50%	0.19%	3.32%	-0.11%
1 Year Performance	-3.89%	4.08%	26.35%	16.46%

STERIS Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STE STERIS	4.8447 of 5 stars	$216.84 +0.4%	$278.00 +28.2%	-4.9%	$21.05B	$5.94B	27.34	17,937	Positive News
BSX Boston Scientific	4.9828 of 5 stars	$44.59 -1.2%	$82.12 +84.2%	-56.7%	$67.09B	$20.07B	18.66	59,000	Analyst Forecast
EW Edwards Lifesciences	3.5063 of 5 stars	$95.17 +0.8%	$96.70 +1.6%	+17.6%	$54.34B	$6.07B	50.62	16,000	Analyst Forecast
IDXX IDEXX Laboratories	4.4708 of 5 stars	$564.98 +1.3%	$751.00 +32.9%	+5.8%	$44.00B	$4.30B	41.60	11,000	Analyst Downgrade
BDX Becton, Dickinson and Company	4.5492 of 5 stars	$155.55 -1.6%	$180.29 +15.9%	-12.5%	$43.56B	$21.84B	39.38	72,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:STE) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

STERIS (STE) Competitors

STE vs. BSX, EW, IDXX, BDX, and RMD

How does STERIS compare to Boston Scientific?

Summary

How does STERIS compare to Edwards Lifesciences?

Summary

How does STERIS compare to IDEXX Laboratories?

Summary

How does STERIS compare to Becton, Dickinson and Company?

Summary

How does STERIS compare to ResMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STE vs. The Competition

STERIS Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

STERIS (STE) Competitors

STE vs. BSX, EW, IDXX, BDX, and RMD

How does STERIS compare to Boston Scientific?

Do institutionals and insiders have more ownership in BSX or STE?

Do analysts rate BSX or STE?

Which has stronger valuation and earnings, BSX or STE?

Is BSX or STE more profitable?

Does the media refer more to BSX or STE?

Which has more volatility & risk, BSX or STE?

Summary

How does STERIS compare to Edwards Lifesciences?

Do insiders & institutionals have more ownership in EW or STE?

Do analysts recommend EW or STE?

Which has preferable valuation & earnings, EW or STE?

Which has more risk & volatility, EW or STE?

Is EW or STE more profitable?

Does the media refer more to EW or STE?

Summary

How does STERIS compare to IDEXX Laboratories?

Do analysts prefer STE or IDXX?

Which has better earnings & valuation, STE or IDXX?

Which has more risk & volatility, STE or IDXX?

Do institutionals & insiders believe in STE or IDXX?

Is STE or IDXX more profitable?

Does the media prefer STE or IDXX?

Summary

How does STERIS compare to Becton, Dickinson and Company?

Does the media favor STE or BDX?

Is STE or BDX more profitable?

Do analysts rate STE or BDX?

Which has preferable valuation and earnings, STE or BDX?

Is STE or BDX a better dividend stock?

Which has more volatility and risk, STE or BDX?

Do institutionals & insiders have more ownership in STE or BDX?

Summary

How does STERIS compare to ResMed?

Does the media refer more to STE or RMD?

Which has more volatility and risk, STE or RMD?

Is STE or RMD more profitable?

Do analysts prefer STE or RMD?

Which has stronger valuation & earnings, STE or RMD?

Do insiders & institutionals believe in STE or RMD?

Is STE or RMD a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STE vs. The Competition

STERIS Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools